BR112013008407A2 - antígenos de clostridium difficile - Google Patents

antígenos de clostridium difficile

Info

Publication number
BR112013008407A2
BR112013008407A2 BR112013008407A BR112013008407A BR112013008407A2 BR 112013008407 A2 BR112013008407 A2 BR 112013008407A2 BR 112013008407 A BR112013008407 A BR 112013008407A BR 112013008407 A BR112013008407 A BR 112013008407A BR 112013008407 A2 BR112013008407 A2 BR 112013008407A2
Authority
BR
Brazil
Prior art keywords
amino acid
acid sequence
antigens
difficile
sequence
Prior art date
Application number
BR112013008407A
Other languages
English (en)
Portuguese (pt)
Inventor
April Roberts
Clifford Shone
Helen Ahern
John Landon
Michael Maynard-Smith
Original Assignee
Micropharm Ltd
Sec Dep For Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micropharm Ltd, Sec Dep For Health filed Critical Micropharm Ltd
Publication of BR112013008407A2 publication Critical patent/BR112013008407A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013008407A 2010-10-05 2011-10-05 antígenos de clostridium difficile BR112013008407A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1016742.7A GB201016742D0 (en) 2010-10-05 2010-10-05 Clostridium difficile antigens
PCT/GB2011/051910 WO2012046061A2 (en) 2010-10-05 2011-10-05 Clostridium difficile antigens

Publications (1)

Publication Number Publication Date
BR112013008407A2 true BR112013008407A2 (pt) 2016-06-21

Family

ID=43243528

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013008407A BR112013008407A2 (pt) 2010-10-05 2011-10-05 antígenos de clostridium difficile

Country Status (10)

Country Link
US (4) US10369206B2 (https=)
EP (1) EP2625193B1 (https=)
JP (1) JP6377907B2 (https=)
CN (1) CN103237807B (https=)
AU (1) AU2011311321B2 (https=)
BR (1) BR112013008407A2 (https=)
CA (1) CA2812731C (https=)
GB (1) GB201016742D0 (https=)
SG (1) SG189058A1 (https=)
WO (1) WO2012046061A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
TWI815599B (zh) 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
HUE037126T2 (hu) * 2011-05-27 2018-08-28 Glaxosmithkline Biologicals Sa Immunogén készítmény
WO2013084071A2 (en) * 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN109776676A (zh) * 2012-11-28 2019-05-21 Cnj控股公司 针对艰难梭菌的抗体
CN103865938B (zh) * 2012-12-16 2016-10-05 山东国际生物科技园发展有限公司 艰难梭菌外毒素a羧基端序列密码子优化基因片段、表达载体构建方法及其表达蛋白的应用
US9493518B2 (en) 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
GB201309421D0 (en) * 2013-05-24 2013-07-10 Imp Innovations Ltd Polypeptides
CN103772509B (zh) * 2014-01-20 2017-01-11 山东国际生物科技园发展有限公司 一种艰难梭菌毒素a/b的融合蛋白及其编码基因与应用
EP3344276B1 (en) * 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
WO2019143552A1 (en) * 2018-01-16 2019-07-25 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
WO2020125707A1 (en) * 2018-12-19 2020-06-25 Tsinghua University Mtu δi-cm intein variant and the use thereof
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
WO2022174229A1 (en) * 2021-02-09 2022-08-18 Joby Aero, Inc. Aircraft propulsion unit
CN113717263B (zh) * 2021-08-04 2022-06-07 河北医科大学第二医院 一种艰难梭菌特异性抗原肽
CN115093470B (zh) * 2022-06-30 2023-03-24 广州市乾相生物科技有限公司 内含肽Mtu RecA突变体及其在生产谷胱甘肽GSH中的应用
CN120484111B (zh) * 2025-05-14 2025-10-28 广州海绿生物技术有限公司 一种包含益生菌的组合物及其在治疗肠胃疾病中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
NZ295998A (en) * 1994-10-24 1999-10-28 Ophidian Pharm Inc Neutralizing antitoxins against clostridium difficile and clostidium botulinum toxins
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
EP1000155A1 (en) 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
JP2002542169A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
WO2002062379A2 (en) 2001-02-09 2002-08-15 The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabeth Clostridium difficile vaccine
DK2270045T3 (en) * 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
WO2007146139A2 (en) 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
CA2733425A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
TWI815599B (zh) * 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法

Also Published As

Publication number Publication date
SG189058A1 (en) 2013-05-31
US20190328859A1 (en) 2019-10-31
EP2625193A2 (en) 2013-08-14
AU2011311321A1 (en) 2013-04-11
WO2012046061A2 (en) 2012-04-12
GB201016742D0 (en) 2010-11-17
CN103237807A (zh) 2013-08-07
US20130266583A1 (en) 2013-10-10
CN103237807B (zh) 2016-10-26
AU2011311321B2 (en) 2016-05-19
EP2625193B1 (en) 2018-04-04
US12491239B2 (en) 2025-12-09
US20210369830A1 (en) 2021-12-02
CA2812731A1 (en) 2012-04-12
CA2812731C (en) 2021-07-06
JP6377907B2 (ja) 2018-08-22
JP2014502253A (ja) 2014-01-30
US20230165949A1 (en) 2023-06-01
WO2012046061A3 (en) 2012-12-20
US10369206B2 (en) 2019-08-06

Similar Documents

Publication Publication Date Title
BR112013008407A2 (pt) antígenos de clostridium difficile
BR112014024751A2 (pt) antígenos de clostridium difficile
BR112017008165B8 (pt) anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
BR112019008702A2 (pt) polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição.
MX351682B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
EA201500741A1 (ru) ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
BR112017003582A2 (pt) anticorpos, composições e usos
BR112015004022A2 (pt) aminoácidos modificados compreendendo um grupo azido
MX357505B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
PE20141561A1 (es) Anticuerpos anti-lrp5 y metodos de uso
EA201390820A1 (ru) Слитый белок против рака
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
UA108778C2 (xx) Протираковий злитий протеїн
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
BR112015023886A2 (pt) polipeptídeo, ácido nucleico, composição farmacêutica, e, método
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
BR112019003462A2 (pt) proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral
BR112016016103A2 (pt) Composição de antígenos micobacterianos
BR112021026831A2 (pt) Proteínas de ligação ao antígeno anti-carcinoma de células escamosas esofágicas new york 1 (ny-eso-1) e métodos de uso das mesmas
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25B Requested transfer of rights rejected

Owner name: THE SECRETARY OF STATE FOR HEALTH (UK) , MICROPHAR